Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

AscellaHealth Releases Q3 2024 Specialty & Rare Pipeline Digest™: FDA-Approved Biosimilars Outpaces Cell and Gene Therapy Amid Complex Regulatory Challenges

AscellaHealth Pipeline Digest

BERWYN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today released its latest Specialty & Rare Pipeline Digest™, the industry’s most comprehensive digital resource of new, pending and upcoming specialty and rare disease drug launches, cell and gene therapies (CGTs) and biosimilars. This complimentary quarterly publication provides timely product updates to support the specialty drug market needs of stakeholders and decision-makers.

“The latest data reveals continual growth in biosimilar approvals, while newly approved CGTs have seen only modest increases due to ongoing regulatory and manufacturing challenges,” says Andy Szczotka, PharmD, chief pharmacy officer, AscellaHealth. “Although these advanced therapies can be transformative for individuals with chronic conditions or rare disease lacking treatment options, the approval and expansion rates for CGTs remain slow.”

According to the data, FDA-approved biosimilars increased from 47 in Q1 to 60 by Q3, providing additional choices for more affordable healthcare treatment options. The rise in interchangeable biosimilars, from 8 to 14, emphasizes the value of biologics that can be substituted at the pharmacy, where state laws permit, for the reference product without the need for a prescriber’s intervention. Interchangeable biosimilars offer opportunities to enhance patient access and lower healthcare costs, similar to the way generic drugs are routinely substituted for brand-name drugs.

Szczotka explains, “The number of approved gene therapies fell from seven in Q2 to five in Q3, while cell therapies stayed steady at three approvals for both quarters. This data underscores the complexities involved in the development, manufacturing and regulatory approval of these advanced treatments. Although CGTs have transformative potential, the approval process remains lengthy and resource intensive.”

Dea Belazi, CEO, AscellaHealth, notes that biosimilars are gaining momentum in the market, providing significant cost-saving opportunities and increasing patient access to essential treatments: “With biosimilar options continuing to grow, providers and healthcare systems will gain more tools for maintaining pricing sustainability,” he says. “The modest progress in CGT approvals reflects the unique challenges these therapies face, including complex clinical trials, regulatory scrutiny and the intricate nature of the manufacturing process. However, every new approval is a vital step forward in advancing personalized medicine for patients with unmet medical needs.”

AscellaHealth facilitates drug commercialization and broadens patient access with a range of innovative end-to-end solutions that support every phase of the product lifecycle. From clinical trials to ensuring smooth patient transitions onto approved therapies, AscellaHealth partners with global life science companies to navigate the complexities of bringing specialty pharmaceuticals to market and improving patient care throughout the entire care continuum.

Access the latest Specialty & Rare Pipeline Digest™ here.

About AscellaHealth LLC
AscellaHealth is a global partner that delivers proven end-to-end solutions to both life sciences and healthcare companies to enhance the quality of life for patients with complex, chronic conditions. A dedicated team gets critical healthcare products from manufacturers to patients while ensuring an efficient flow of funds between payers and pharma. Visit www.AscellaHealth.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a348a29e-eab9-4437-a799-0205007d1ba8

This press release was published by a CLEAR® Verified individual.


Media:
Nicole Dufour
CPR Communications
ndufour@cpronline.com
201.641.1911 x 54

Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.